Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ingram

Showing results (471-480 of 507) with videos related to

Pageof 51
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|December 19, 2024
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: TreatmentC C Zouboulis, F G Bechara, F Benhadou, et al.
The British Journal of Dermatology|August 19, 2021
Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)S Cro, V R Cornelius, A E Pink, et al.
The British Journal of Dermatology|October 29, 2017
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and IIL Thorlacius, A Garg, J R Ingram, et al.
Nature Medicine|May 29, 2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistanceYanshuo Chu, Enyu Dai, Yating Li, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologicsGeorgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, et al.
Experimental Dermatology|October 15, 2020
What causes hidradenitis suppurativa ?-15 years afterChristos C Zouboulis, Farida Benhadou, Angel S Byrd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 27, 2020
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyA Henderson, D L Paterson, M D Chatfield, et al.
Journal of the American Academy of Dermatology|July 7, 2019
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) ProjectAmit Garg, Erica Neuren, Denny Cha, et al.
JAMA Dermatology|September 27, 2023
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus StatementNicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, et al.
The British Journal of Dermatology|September 3, 2022
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE projectBria Midgette, Andrew Strunk, Oleg Akilov, et al.
Pageof 51

Showing results (471-480 of 507) with videos related to

Sort By:
Pageof 51
Journal of the European Academy of Dermatology and Venereology : JEADV|December 19, 2024
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: TreatmentC C Zouboulis, F G Bechara, F Benhadou, et al.
The British Journal of Dermatology|August 19, 2021
Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)S Cro, V R Cornelius, A E Pink, et al.
The British Journal of Dermatology|October 29, 2017
Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and IIL Thorlacius, A Garg, J R Ingram, et al.
Nature Medicine|May 29, 2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistanceYanshuo Chu, Enyu Dai, Yating Li, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2025
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologicsGeorgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, et al.
Experimental Dermatology|October 15, 2020
What causes hidradenitis suppurativa ?-15 years afterChristos C Zouboulis, Farida Benhadou, Angel S Byrd, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 27, 2020
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyA Henderson, D L Paterson, M D Chatfield, et al.
Journal of the American Academy of Dermatology|July 7, 2019
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) ProjectAmit Garg, Erica Neuren, Denny Cha, et al.
JAMA Dermatology|September 27, 2023
Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus StatementNicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, et al.
The British Journal of Dermatology|September 3, 2022
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE projectBria Midgette, Andrew Strunk, Oleg Akilov, et al.
Pageof 51